中信证券股份有限公司 关于深圳市昌红科技股份有限公司 开展远期结售汇业务的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳市昌红 科技股份有限公司（以下简称"昌红科技"或"公司"）2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关法律法规规定，对公司开展远期结售汇业务事项进行 了核查，具体核查情况如下： 一、开展远期结售汇业务的目的 公司及其子公司部分业务需采用外币进行结算，因此当汇率出现较大波动时， 汇兑损益将对公司的业绩造成一定影响。为了提高外汇资金使用效率，合理降低 财务费用，降低汇率波动对公司经营的影响，公司及其子公司拟在商业银行开展 远期结售汇业务。 公司开展远期购汇交易以正常生产经营为基础，以稳健为原则，以货币保值 和降低汇率风险为目的，不做无实际需求的投机性交易，不进行单纯以盈利为目 的外汇交易，通过锁定汇率，降低汇率波动风险。 二、远期结售汇业务的基本情况 公司及控股子公司的远期结售汇业务，是为了满足生产经营进出口 ...

专项报告 | 一、 | 专项报告 | | | 1-2 | | | --- | --- | --- | --- | --- | --- | | 二、 | 汇总表 | 目 | 录 | 页 1-3 | 次 | 关于深圳市昌红科技股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 信会师报字[2025]第 ZL10157 号 关于深圳市昌红科技股份有限公司 非经营性资金占用及其他关联资金往来情况的 深圳市昌红科技股份有限公司全体股东： 我们审计了深圳市昌红科技股份有限公司(以下简称昌红科 技)2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZL10161 号的无保 留意见审计报告。 昌红科技管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所创业板上市公司自律监管指南 第 1 ...

中信证券股份有限公司 关于深圳市昌红科技股份有限公司 向控股子公司提供财务资助的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳市昌红 科技股份有限公司（以下简称"昌红科技"或"公司"）2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关法律法规规定，对公司向控股子公司提供财务资助事 项进行了核查，具体核查情况如下： 一、财务资助事项概述 公司于 2025 年 4 月 24 日召开第六届董事会第十五次会议和第六届监事会 第十二次会议，审议通过了《关于向控股子公司提供财务资助的议案》，为支持 控股子公司浙江鼎龙蔚柏精密技术有限公司（以下简称"鼎龙蔚柏"）业务发展 需要，在不影响公司正常经营的情况下，同意公司以自有资金向鼎龙蔚柏提供不 超过 1,600 万元人民币借款，用于固定资产投资及补充流动资金。同时，鼎龙蔚 柏拟向其控股子公司浙江蔚柏包装科技有限公司（以下简称"蔚柏包装"）提供 不超过 400 万元人民币借款，用于补充流动资金，借 ...

2024 年度内部控制自我评价报告的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳市昌红 科技股份有限公司（以下简称"昌红科技"或"公司"） 2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律法规规定，对公司 2024 年度内部控制自我评 价报告进行了核查，具体核查情况如下： 中信证券股份有限公司 关于深圳市昌红科技股份有限公司 一、公司内部控制的基本情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 2、纳入评价范围的主要业务和事项 （1）内部环境 1）组织架构 根据《公司法》《证券法》等相关法律规定，公司在以前年度的基础上进一 步完善组织架构，股东大会为公司最高权力机构，董事会为决策机构，监事会为 监管机构，经理层为决策执行机构并管理公司日常事务。公司董事会对股东大会 负责，下设战略、审计、薪酬与考核、提名四个专门委员会，其中审计委员会下 设内部审计部。公司根据职责 ...

中信证券股份有限公司关于深圳市昌红科技股份有限公司 使用部分暂时闲置募集资金及闲置自有资金 进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券""保荐人"）作为深圳市昌红科技 股份有限公司（以下简称"昌红科技""公司"）2022 年度向特定对象发行 A 股股票 的保荐人。根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市 公司募集资金管理和使用的监管要求》（以下简称"《上市公司募集资金管理和使用的 监管要求》"）《深圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》"） 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》（以下简 称"《规范运作》"）等相关法律法规和规范性文件的规定，对昌红科技使用部分闲置 募集资金进行现金管理的事项进行了审慎核查，发表如下核查意见： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意深圳市昌红科技股份有限公司向特定对象发 行股票注册的批复》（证监许可〔2023〕1379 号）同意，昌红科技向特定对象发行人民 币普通股（A 股）30,000,000 股，每股面值为 1.00 元，每股发行价格为 13.79 ...

中信证券股份有限公司 关于深圳市昌红科技股份有限公司及子公司向金融机构申 请综合授信额度及对外担保额度预计的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳市昌红 科技股份有限公司（以下简称"昌红科技"或"公司"） 2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律法规规定，对公司及子公司向金融机构申请综 合授信额度及对外担保额度预计事项进行了核查，具体核查情况如下： 一、申请综合授信额度及对外担保额度预计的情况概述 为落实公司发展战略，满足公司及子公司（包括全资子公司和控股子公司） 日常经营及业务发展的需要，公司及子公司拟向银行等金融机构申请总额不超过 人民币 100,000.00 万元综合授信额度，授信品种包括但不限于流动资金贷款、固 定资产贷款、项目贷款、承兑汇票、信用证、票据贴现、金融衍生品等综合业务。 上述授信额度不等同于实际融资金额，公司及子公司将根据具体的授信条件选择 最有利于公司的金融机构，具体业务品种、授信额 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 249,088,234.83, representing a 6.70% increase compared to CNY 233,436,775.43 in the same period last year[5]. - Net profit attributable to shareholders decreased by 28.94% to CNY 17,737,257.55 from CNY 24,959,889.53 year-on-year[5]. - Basic and diluted earnings per share both fell by 40.00% to CNY 0.03 from CNY 0.05[5]. - Total operating revenue for the current period reached ¥249,088,234.83, an increase of 6.1% compared to ¥233,436,775.43 in the previous period[22]. - Net profit for the current period was ¥12,351,745.99, a decrease of 42.0% from ¥21,343,409.98 in the previous period[23]. - Total comprehensive income for the period was CNY 11,901,755.69, compared to CNY 17,037,947.82 in the previous period, reflecting a decrease of approximately 30.5%[24]. - The total comprehensive income attributable to the parent company was CNY 17,287,267.25, compared to CNY 20,654,427.37, a decrease of approximately 16.5%[24]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 51,840,759.82, down 15.73% from CNY 61,518,221.92 in the previous year[5]. - Cash inflow from operating activities totaled CNY 310,568,421.52, an increase of 10.3% from CNY 281,404,992.43 in the previous period[26]. - Cash outflow from investing activities was CNY 479,889,621.42, compared to CNY 351,811,958.58, representing an increase of approximately 36.4%[27]. - Net cash flow from financing activities was CNY 41,183,458.85, a significant improvement from a negative CNY 6,941,433.43 in the previous period[27]. - The company reported a net cash decrease of CNY 4,640,200.42 for the period, compared to a decrease of CNY 58,788,544.62 in the previous period[27]. - Cash and cash equivalents at the end of the period were CNY 321,623,308.87, down from CNY 641,384,957.64, indicating a decrease of about 50%[27]. Assets and Liabilities - Total assets increased by 1.95% to CNY 2,512,578,592.51 compared to CNY 2,464,470,524.07 at the end of the previous year[5]. - Current liabilities totaled ¥321,416,802.48, an increase of 12.8% from ¥284,914,336.13 in the previous period[21]. - Non-current liabilities remained stable at ¥520,532,051.76, slightly down from ¥520,628,381.36 in the previous period[21]. - The company's equity attributable to shareholders rose by 1.05% to CNY 1,648,197,990.05 from CNY 1,631,110,546.79[5]. - The company's equity attributable to shareholders increased to ¥1,648,197,990.05, up from ¥1,630,910,546.79 in the previous period[21]. Shareholder Information - The largest shareholder, Li Huanchang, holds 202,696,900 shares, representing 38.06% of the total share capital, with 152,022,675 shares pledged[15]. - The top 10 shareholders collectively hold 202,959,400 shares, accounting for 38.11% of the total share capital[15]. - The company has a total of 163,811,713 shares under lock-up conditions, with no shares released during the current period[17]. - There are no changes in the number of shares lent or returned by the top shareholders due to margin trading activities[15]. Other Income and Expenses - Other income decreased by 36.52% to CNY 315.74 from CNY 497.38, primarily due to reduced government subsidies[11]. - Investment income turned negative at CNY -49.61, a decline of 133.53% from CNY 147.99, mainly due to losses from an associated company[11]. - Total operating costs increased to ¥233,383,776.18, up 8.7% from ¥214,740,980.94 in the previous period[22]. - Research and development expenses for the current period were ¥12,614,904.31, compared to ¥12,010,175.12 in the previous period, indicating a 5.0% increase[23]. Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in the current report[18]. - The company has not reported any significant mergers or acquisitions in the current period[18].

Financial Performance - The company's operating revenue for 2024 reached ¥1,038,898,133.44, an increase of 11.56% compared to ¥931,271,438.81 in 2023[19]. - Net profit attributable to shareholders for 2024 was ¥101,963,473.13, representing a significant increase of 222.11% from ¥31,655,146.81 in 2023[19]. - The net profit after deducting non-recurring gains and losses was ¥85,544,955.85, up 348.15% from ¥19,088,608.07 in 2023[19]. - The basic earnings per share for 2024 was ¥0.19, a 216.67% increase from ¥0.06 in 2023[19]. - The total assets at the end of 2024 were ¥2,464,270,524.07, a decrease of 3.57% from ¥2,555,436,436.76 at the end of 2023[19]. - The weighted average return on equity for 2024 was 6.23%, up from 2.27% in 2023[19]. - The net cash flow from operating activities for 2024 was ¥173,916,844.05, a decrease of 10.00% compared to ¥193,243,973.94 in 2023[19]. - The company reported a total of ¥16,418,517.28 in non-recurring gains for 2024, compared to ¥12,566,538.74 in 2023[25]. - The company's total revenue for the reporting period was 1,038.90 million RMB, an increase of 11.56% compared to the same period last year[83]. - Net profit attributable to shareholders was 101.96 million RMB, representing a significant growth of 222.11% year-over-year[83]. - Basic earnings per share rose to 0.19 RMB, reflecting a 216.67% increase compared to the previous year[83]. Dividend Distribution - The company plans to distribute a cash dividend of 0.75 RMB per 10 shares to all shareholders, based on a total of 532,508,690 shares[5]. - Cumulative cash dividends for 2024 are projected to be 718.89 million yuan, accounting for 70.50% of the net profit attributable to shareholders[170]. Governance and Compliance - The company has a comprehensive governance structure, with all board members present for the report's approval, ensuring accountability and transparency[5]. - The financial report is guaranteed to be true, accurate, and complete by the company's leadership, including the chairman and accounting heads[5]. - The company is subject to regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, ensuring compliance with national financial laws[12]. - The company emphasizes technological innovation and R&D strength, investing in new technologies and materials to maintain industry-leading product performance and quality[76]. - The company has established a market value management system to enhance its market management practices and protect investor rights[168]. - The company has complied with all relevant laws and regulations regarding corporate governance, with no significant discrepancies identified[185]. Market and Industry Insights - The company is engaged in the specialized equipment manufacturing industry, focusing on medical devices, smart manufacturing, and semiconductor materials[28]. - The medical device industry is experiencing rapid growth driven by healthcare system reforms and increasing domestic demand for high-quality medical equipment[35]. - The global medical device market size in 2023 was $582.6 billion, with a five-year compound growth rate of approximately 6.37%[30]. - China's medical device market size reached 1.27 trillion yuan in 2023, with a compound annual growth rate exceeding 10%[30]. - The "14th Five-Year Plan" emphasizes the need for innovation in medical devices and pharmaceuticals, aiming to strengthen the public health system[30]. - The company is focusing on expanding its presence in the assisted reproductive technology sector with innovative tools like embryo culture dishes and sperm collection cups[59]. Research and Development - The company has established a comprehensive R&D system, including the Guangdong Precision Injection Mold Engineering Technology Research Center and the Shanghai Emerging Medical Devices and Life Sciences R&D Center, focusing on industry technology hotspots and challenges[67]. - The company focuses on independent R&D, enhancing precision mold manufacturing, automation production integration, and precision injection molding technology, continuously upgrading processing technology and design capabilities[66]. - Continuous investment in R&D and product innovation is a key focus, particularly in the development of high-performance materials for medical consumables[80]. - The company has seven products under research, with several entering the "small batch and verification" stage at domestic mainstream wafer manufacturers[88]. Strategic Initiatives - The company has plans for market expansion and new product development in the specialized equipment sector[28]. - The company aims to leverage its R&D capabilities to develop new technologies that address emerging healthcare challenges and improve patient outcomes[60]. - The company is investing in smart manufacturing technologies to enhance production efficiency and product quality[62]. - The company plans to enhance its global industrial chain layout and increase its production capacity in the high-end medical device sector, with a focus on expanding its market presence in Southeast Asia[146][148]. Financial Management - The company has maintained good management of raised funds, ensuring compliance with the three-party supervision agreement with banks and sponsors[131]. - The company has established dedicated accounts for the management of raised funds, ensuring strict approval processes for their use[131]. - The company has reported a total of 776,697.55 yuan in surplus funds from the high-end medical equipment and consumables production line expansion project, which will be permanently used to supplement working capital[134]. - The company has achieved a cumulative investment of 9.88 million in specific projects, with 100% of the investment completed by the end of the reporting period[132]. Operational Efficiency - The company is enhancing its information technology infrastructure to improve management efficiency and reduce costs[91]. - The production is customer demand-oriented, with production plans based on annual sales targets and actual order volumes, ensuring efficient resource allocation[71]. - The company has a complete after-sales service team, providing high-quality support, product upgrades, and technical training to maintain long-term customer relationships[72]. Talent and Human Resources - The company has a talent pool of over 500 individuals across R&D, production, sales, and management, focusing on enhancing high-end talent reserves[150]. - The company is actively recruiting high-quality talent and optimizing its internal control systems to address management risks associated with business expansion[165]. Shareholder Engagement - The company held 3 shareholder meetings in 2024, ensuring equal rights for all shareholders and protecting the interests of minority investors[174]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with legal regulations[179].

昌红科技（300151）公告，2025年第一季度营业收入2.49亿元，同比增长6.70%。净利润1773.73万元， 同比下降28.94%。 ...

此次颁奖典礼上，罗氏授予昌红科技"五载精诚协作，共筑诊断未来"奖项，以表彰双方在过去五年合作 中所做出的卓越贡献。罗氏诊断仪器制造全球负责人Joerg Spielmann先生在颁奖现场表示，罗氏拥有 120多年的历史，与昌红科技的合作在过去五年尤为重要。他再次肯定了昌红科技的努力，并期待双方 在未来能够进行更紧密的合作。 日前，罗氏与昌红科技（300151）在浙江柏明胜医疗产业园举办五周年合作颁奖典礼。此次活动不仅是 对双方五年来紧密合作的高度肯定，更是对未来携手共进的美好展望。 罗氏诊断仪器制造全球负责人Joerg Spielmann、亚太区仪器本土化项目负责人Laura Bischoff、罗氏诊断 仪器制造苏州负责人Ben Fu、罗氏苏州采购总监Jason Liu，与昌红科技董事长李焕昌、柏明胜医疗总经 理罗红志、副总经理孙章辉、营销总监陈杰泉等领导共同出席本次活动。 双方团队回顾合作历程，昌红科技凭借其在精密模具和注塑成型领域的核心技术，为罗氏提供了高品质 的产品，取得罗氏的高度认可，通过稳定的供应链和高质量的产品，为双方的合作提供了坚实保障。昌 红科技表示，公司将不断优化风险教育、沉淀技术经验，并通过 ...